Abivax SA American Depositary Shares (ABVX)

Price$122.47

Favorite Metrics

Price vs S&P 500 (26W)27.15%

Price vs S&P 500 (4W)-11.30%

Market Capitalization$9.68B

All Metrics

Book Value / Share (Quarterly)$0.75

P/TBV (Annual)12.67x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-2.52

Price vs S&P 500 (YTD)-15.84%

EPS (TTM)$-4.61

10-Day Avg Trading Volume0.13M

EPS Excl Extra (TTM)$-4.61

EPS (Annual)$-5.04

ROI (Annual)-128.85%

Gross Margin (Annual)-19700.00%

Cash / Share (Quarterly)$1.28

ROA (Last FY)-85.88%

EBITD / Share (TTM)$-4.32

ROE (5Y Avg)-460.64%

Cash Flow / Share (Annual)$-2.88

P/B Ratio202.41x

P/B Ratio (Quarterly)10.61x

Net Income / Employee (Annual)$-6

Net Interest Coverage (TTM)-115.56x

ROA (TTM)-151.13%

EPS Incl Extra (Annual)$-5.04

Current Ratio (Annual)1.82x

Quick Ratio (Quarterly)0.77x

3-Month Avg Trading Volume0.18M

52-Week Price Return1877.10%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.63

P/S Ratio (Annual)821456.70x

Asset Turnover (Annual)0.00x

52-Week High$132.00

EPS Excl Extra (Annual)$-5.04

CapEx CAGR (5Y)-7.33%

Tangible BV CAGR (5Y)22.28%

26-Week Price Return31.14%

Quick Ratio (Annual)1.78x

13-Week Price Return-0.38%

Total Debt / Equity (Annual)2.37x

Current Ratio (Quarterly)0.77x

Enterprise Value$9,703.134

Book Value / Share Growth (5Y)-7.90%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-58600.00%

Cash / Share (Annual)$2.82

3-Month Return Std Dev51.42%

Net Income / Employee (TTM)$-4

ROE (Last FY)-434.26%

Net Interest Coverage (Annual)-16.41x

EPS Basic Excl Extra (Annual)$-5.04

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)2.37x

EPS Incl Extra (TTM)$-4.61

Receivables Turnover (Annual)0.00x

ROI (TTM)-98.12%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.63

Price vs S&P 500 (52W)1847.27%

Year-to-Date Return-13.95%

5-Day Price Return-1.80%

EPS Normalized (Annual)$-5.04

ROA (5Y Avg)-60.32%

Net Profit Margin (Annual)-50800.00%

Month-to-Date Return10.68%

Cash Flow / Share (TTM)$-3.53

EBITD / Share (Annual)$-4.95

Operating Margin (Annual)-57900.00%

LT Debt / Equity (Annual)1.26x

ROI (5Y Avg)-91.49%

LT Debt / Equity (Quarterly)1.26x

EPS Basic Excl Extra (TTM)$-4.61

P/TBV (Quarterly)12.67x

P/B Ratio (Annual)10.61x

Book Value / Share (Annual)$0.75

Price vs S&P 500 (13W)-1.07%

Beta1.09x

Revenue / Share (TTM)$0.00

ROE (TTM)-211.43%

52-Week Low$5.00

About

Abivax is a French clinical-stage biotechnology company developing therapeutics designed to regulate immune response in chronic inflammatory diseases. The company's lead candidate, obefazimod, is in Phase 3 development for moderately to severely active ulcerative colitis. Abivax focuses on inflammatory bowel disease, including both ulcerative colitis and Crohn's disease.